Sydney-based Pharmaxis(ASX:PXS) has announced it is progressing the development of an oral anti‐fibrotic Lysyl Oxidase (LOX) inhibitor for the treatment of myelofibrosis and pancreatic cancer. …
Latest Video
New Stories
-
New leadership for AbbVie Australia
December 12, 2019 - - Latest News -
Key trade agreement scraps pharma IP provision
December 12, 2019 - - Latest News -
Still time to take advantage of BioPharmaDispatch 2020 early registration
December 12, 2019 - - Latest News -
MRFF program for issues identified by PBAC
December 12, 2019 - - Latest News -
MA board reappoints Dr Anna Lavelle
December 12, 2019 - - Latest News -
MSD announces US$2.7bn acquisition of ArQule
December 11, 2019 - - Latest News -
Sanofi narrows focus and scraps R&D in heritage areas
December 11, 2019 - - Latest News